Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: Implications for HCMV immunotherapy

European Journal of Immunology

Volumn 35, Issue 3, 2005, Pages 996-1007

  Rist, Michael ^a   Cooper, Leanne ^a   Elkington, Rebecca ^a   Walker, Susan ^a   Fazou, Chrysa ^a   Tellam, Judy ^a   Crough, Tania ^a   Khanna, Rajiv ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antigens peptides epitopes; Cytotoxic T cells; Immunotherapy; Virus

Indexed keywords

CYTOMEGALOVIRUS VACCINE; EPITOPE; HLA ANTIGEN CLASS 1; RECOMBINANT VACCINE;

ADENOVIRUS; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL STIMULATION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; EX VIVO STUDY; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS INFECTIVITY; VIRUS REACTIVATION;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CELL LINE; CYTOMEGALOVIRUS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC TECHNIQUES; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 15844410585     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425746     Document Type: Article

References (52)

1. Alford, C. A., Stagno, S., Pass, R. F. and Britt, W. J., Congenital and perinatal cytomegalovirus infections. Rev. Infect. Dis. 1990. 12 Suppl 7: S745-S753.
2. Sissons, J. G., Carmichael, A. J., McKinney, N., Sinclair, J. H. and Wills, M. R., Human cytomegalovirus and immunopathology. Springer Semin. Immunopathol. 2002. 24: 169-185.
3. Zaia, J. A. and Forman, S. J., Cytomegalovirus infection in the bone marrow transplant recipient. Infect. Dis. Clin. North Am. 1995. 9: 879-900.
4. Gandhi, M. K., Wills, M. R., Sissons, J. G. and Carmichael, A. J., Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev. 2003. 17: 259-264.
5. Zaia, J. A., Gallez-Hawkins, G. M., Tegtmeier, B. R., ter Veer, A., Li, X., Niland, J. C. and Forman, S. J., Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect. Dis. 1997. 176: 782-785.
6. Ljungman, P., Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant. 1998. 21 Suppl 2: S72-S74.
7. Ljungman, P., Brand, R., Einsele, H., Frassoni, F., Niederwieser, D. and Cordonnier, C., Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003. 102: 4255-4260.
8. Ljungman, P., Reusser, P., de la Camara, R., Einsele, H., Engelhard, D., Ribaud, P. and Ward, K., Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004. 33: 1075-1081.
9. Peggs, K. S., Verfuerth, S., Pizzey, A., Khan, N., Guiver, M., Moss, P. A. and Mackinnon, S., Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T cell lines. Lancet 2003. 362: 1375-1377.
10. Moss, P. A., Cobbold, M. and Craddock, C., The cellular immunotherapy of viral infection. Transfus. Med. 2003. 13: 405-415.
11. Meijer, E., Boland, G. J. and Verdonck, L. F., Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin. Microbiol. Rev. 2003. 16: 647-657.
12. Einsele, H., Roosnek, E., Rufer, N., Sinzger, C., Riegler, S., Loffler, J., Grigoleit, U., Moris, A., Rammensee, H. G., Kanz, L. et al., Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002. 99: 3916-3922.
13. + T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 1998. 16: 2752-2760.
14. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother. 1998. 7: 437-448.
15. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin. Cancer Res. 2000. 6: 1997-2005.
16. Savage, P., Cowburn, P., Clayton, A., Man, S., McMichael, A., Lemoine, N., Epenetos, A. and Ogg, G., Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. Br. J. Cancer 2002. 86: 1336-1342.
17. Oelke, M., Maus, M. V., Didiano, D., June, C. H., Mackensen, A. and Schneck, J. P., Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 2003. 9: 619-624.
18. Latouche, J. B. and Sadelain, M., Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol. 2000. 18: 405-409.
19. Hamel, Y., Rohrlich, P., Baron, V., Bonhomme, D., Rieux-Laucat, F., Necker, A., Lemonnier, F., Ferradini, L., Fischer, A. and Cavazzana-Calvo, M., Characterization of antigen-specific repertoire diversity following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus pp65. Eur. J. Immunol. 2003. 33: 760-768.
20. Hamel, Y., Blake, N., Gabrielsson, S., Haigh, T., Jooss, K., Martinache, C., Caillat-Zucman, S., Rickinson, A. B., Hacein-Bey, S., Fischer, A. and Cavazzana-Calvo, M., Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum. Gene Ther. 2002. 13: 855-866.
21. Gottschalk, S., Edwards, O. L., Sili, U., Huls, M. H., Goltsova, T., Davis, A. R., Heslop, H. E. and Rooney, C. M., Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003. 101: 1905-1912.
22. Leen, A. M., Sili, U., Savoldo, B., Jewell, A. M., Piedra, P. A., Brenner, M. K. and Rooney, C. M., Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004. 103: 1011-1019.
23. Thimme, R., Oldach, D., Chang, K. M., Steiger, C., Ray, S. C. and Chisari, F. V., Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001. 194: 1395-1406.
24. +-T cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 2003. 77: 5226-5240.
25. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 2002. 76: 12584-12595.
26. + cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 1995. 92: 5845-5849.
27. Thomson, S. A., Sherritt, M. A., Medveczky, J., Elliott, S. L., Moss, D. J., Fernando, G. J., Brown, L. E. and Suhrbier, A., Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. 1998. 160: 1717-1723.
28. Yotnda, P., Onishi, H., Heslop, H. E., Shayakhmetov, D., Lieber, A., Brenner, M. and Davis, A., Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001. 8: 930-937.
29. Dawson, D. V., Ozgur, M., Sari, K., Ghanayem, M. and Kostyu, D. D., Ramifications of HLA class I polymorphism and population genetics for vaccine development. Genet. Epidemiol. 2001. 20: 87-106.
30. Mocarski, E. S. J., Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002. 10: 332-339.
31. Farrell, H. E., Davis-Poynter, N. J., Andrews, D. M. and Degli-Esposti, M. A., Function of CMV-encoded MHC class I homologues. Curr. Top. Microbiol. Immunol. 2002. 269: 131-151.
32. Stewart, A. K., Lassam, N. J., Quirt, I. C., Bailey, D. J., Rotstein, L. E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y. et al., Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999. 6: 350-363.
33. Kusumoto, M., Umeda, S., Ikubo, A., Aoki, Y., Tawfik, O., Oben, R., Williamson, S., Jewell, W. and Suzuki, T., Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 2001. 50: 373-381.
34. Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H. et al., Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 1998. 90: 1894-1900.
35. Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. and Nabel, G. J., Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000. 408: 605-609.
36. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L., Dubey, S. A. et al., Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002. 415: 331-335.
37. Alexander-Miller, M. A., Derby, M. A., Sarin, A., Henkart, P. A. and Berzofsky, J. A., Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 1998. 188: 1391-1399.
38. Palmowski, M. J., Choi, E. M., Hermans, I. F., Gilbert, S. C., Chen, J. L., Gileadi, U., Salio, M., Van Pel, A., Man, S., Bonin, E. et al., Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 2002. 168: 4391-4398.
39. Mizuguchi, H. and Kay, M. A., Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 1998. 9: 2577-2583.
40. Mizuguchi, H. and Kay, M. A., A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 1999. 10: 2013-2017.
41. Burrows, S. R., Rodda, S. J., Suhrbier, A., Geysen, H. M. and Moss, D. J., The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 1992. 22: 191-195.
42. Riddell, S. R., Reusser, P. and Greenberg, P. D., Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev. Infect. Dis. 1991. 13 Suppl 11: S966-S973.
43. Browne, H., Smith, G., Beck, S. and Minson, T., A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 1990. 347: 770-772.
44. Britt, W. J., Vugler, L., Butfiloski, E. J. and Stephens, E. B., Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990. 64: 1079-1085.
45. Khanna, R., Jacob, C. A., Burrows, S. R., Kurilla, M. G., Kieff, E., Misko, I. S., Sculley, T. B. and Moss, D. J., Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology 1991. 74: 504-510.
46. Khanna, R., Burrows, S. R., Kurilla, M. G., Jacob, C. A., Misko, I. S., Sculley, T. B., Kieff, E. and Moss, D. J., Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 1992. 176: 169-176.
47. Khanna, R., Jacob, C. A., Burrows, S. R. and Moss, D. J., Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 1993. 164: 41-49.
48. Longmate, J., York, J., La Rosa, C., Krishnan, R., Zhang, M., Senitzer, D. and Diamond, D. J., Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001. 52: 165-173.
49. Wills, M. R., Carmichael, A. J., Mynard, K., Jin, X., Weekes, M. P., Plachter, B. and Sissons, J. G., The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J. Virol. 1996. 70: 7569-7579.
50. Burrows, S. R., Elkington, R. A., Miles, J. J., Green, K. J., Walker, S., Haryana, S. M., Moss, D. J., Dunckley, H., Burrows, J. M. and Khanna, R., Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype. J. Immunol. 2003. 171: 1407-1412.
51. Khattab, B. A., Lindenmaier, W., Frank, R. and Link, H., Three T cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes. J. Med. Virol. 1997. 52: 68-76.
52. Gavin, M. A., Gilbert, M. J., Riddell, S. R., Greenberg, P. D. and Bevan, M. J., Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 1993. 151: 3971-3980.